Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease

Ramusino, M. C.; Garibotto, V.; Bacchin, R.; Altomare, D.; Dodich, A.; Assal, F.; Mendes, A.; Costa, A.; Tinazzi, M.; Morbelli, S. D.; Bauckneht, M.; Picco, A.; Dottorini, M. E.; Tranfaglia, C.; Farotti, L.; Salvadori, N.; Moretti, D.; Savelli, G.; Tarallo, A.; Nobili, F.; Parapini, M.; Cavaliere, Maria Caterina; Salvatore, E.; Salvatore, M.; Boccardi, M.; Frisoni, G. B.

doi:10.1007/s00259-019-04466-6

To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm. METHODS: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker. RESULTS: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3. CONCLUSIONS: Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence.

Scheda prodotto non validato

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Risorse UNIGE

Titolo:	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease
Autori:	Ramusino M. C. Garibotto V. Bacchin R. Altomare D. Dodich A. Assal F. Mendes A. Costa A. Tinazzi M. MORBELLI, SILVIA DANIELA BAUCKNEHT, MATTEO PICCO, AGNESE Dottorini M. E. Tranfaglia C. Farotti L. Salvadori N. Moretti D. Savelli G. Tarallo A. NOBILI, FLAVIO MARIANO Parapini M. CAVALIERE, MARIA CATERINA Salvatore E. Salvatore M. Boccardi M. Frisoni G. B. mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2020
Rivista:	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Abstract:	To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm. METHODS: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker. RESULTS: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.028) and 3 (CSF 0%; PET 78%, P < 0.001); PET induced a diagnostic confidence increase significantly higher than CSF on both rounds 2 and 3. CONCLUSIONS: Amyloid-PET should be prioritized over CSF biomarkers in the diagnostic workup of patients investigated for suspected AD, as it provides greater changes in diagnosis and diagnostic confidence.
Handle:	http://hdl.handle.net/11567/970269
Appare nelle tipologie:	01.01 - Articolo su rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11567/970269

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

Scheda prodotto non validato

File in questo prodotto: